Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults

[Business Wire] – Bristol-Myers Squibb Company announced today that the European Commission has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults without known mutations associated . . . → Read More: Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen Stock Update (NYSE:BMY): U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults